tbuckley/cabot-search huggingface dataset:
Is bone marrow sparing intensity modulated radiotherapy better than 3-dimensional conformal radiotherapy in reducing haematological toxicities during pelvic irradiation in locally advanced carcinoma cervix?: A prospective study
Authors: A. Elangovan, A. Bahl, F.D. Patel, C.B. Dracham, B. Rai, G. Trivedi
Journal: Annals of Oncology (2018)
Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis
Authors: Hongwei Liu, Junming Bi, Wei Dong, Meihua Yang, Juanyi Shi, Ning Jiang, Tianxin Lin, Jian Huang
Journal: Molecular Cancer (2018)

Increasing evidence has revealed that circular RNAs (circRNAs) play crucial roles in cancer biology. However, the role and underlying regulatory mechanisms of circFNDC3B in bladder cancer (BC) remain unknown. A cell invasion model was established by repeated transwell assays, and invasion-related circRNAs in BC were identified through an invasion model. The expression of circFNDC3B was detected in 82 BC tissues and cell lines by quantitative real-time PCR. Functional assays were performed to evaluate the effects of circFNDC3B on proliferation, migration and invasion in vitro-, and on tumorigenesis and metastasis in vivo. The relationship between circFNDC3B and miR-1178-3p was confirmed by fluorescence in situ hybridization, pull-down assay and luciferase reporter assay. In the present study, we identified a novel circRNA (circFNDC3B) through our established BC cell invasion model. We found that circFNDC3B was dramatically downregulated in BC tissues and correlated with pathological T stage, grade, lymphatic invasion and patients' overall survival rate. Functionally, overexpression of circFNDC3B significantly inhibited proliferation, migration and invasion both in vitro and in vivo. Mechanistically, circFNDC3B could directly bind to miR-1178-3p, which targeted the 5′UTR of the oncogene G3BP2. Moreover, circFNDC3B acted as a miR-1178-3p sponge to suppress G3BP2, thereby inhibiting the downstream SRC/FAK signaling pathway. CircFNDC3B may serve as a novel tumor suppressive factor and potential target for new therapies in human BC.
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Authors: Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub-de Hooge, Annelies Jorritsma-Smit, Ronald Boellaard, Iris C. Kok, Sjoukje F. Oosting, Carolina P. Schröder, T. Jeroen N. Hiltermann, Anthonie J. van der Wekken, Harry J. M. Groen, Thomas C. Kwee, Sjoerd G. Elias, Jourik A. Gietema, Sandra Sanabria Bohorquez, Alex de Crespigny, Simon-Peter Williams, Christoph Mancao, Adrienne H. Brouwers, Bernard M. Fine, Elisabeth G. E. de Vries
Journal: Nature Medicine (2018)
Features and Outcome of Chronic Myeloid Leukemia (CML) at Very Young Age: Data from the International Pediatric CML Registry (I-CML-Ped Study)
Authors: Adalet Meral Gunes, Frédéric Millot, Krzysztof Kalwak, Birgitte Lausen, Petr Sedlacek, Birgitte Versluijs, Michael Dworzak, Barbara De Moerloose, Meinolf Suttorp
Journal: Blood (2018)
The transcription factor Sox9 is required for the differentiation of Paneth cells in the intestinal epithelium
Authors: Yuko Mori-Akiyama, Stanley R. Hamilton, Hans Clevers, Benoit De Crombrugghe
Journal: Cancer Research (2006)

3955  In the crypts of the intestinal epithelium, undifferentiated multipotent stem cells give rise to proliferating transient cells, which differentiate into four epithelial cell types: enterocytes, goblet cells, enteroendocrine cells, and Paneth cells. Whereas Paneth cells migrate towards the bottom of the crypts, the other cell types migrate up the crypt-villi axis and are shed into the lumen. Sox9 is a target gene of Wnt/β-catenin in epithelial cells of the intestinal crypts and duplicates the pattern of expression of β-catenin in these cells, i.e. in stem cells, proliferative transient cells and Paneth cells. In other tissues Sox9 is required for the differentiation of a discrete number of distinct cell types including chondrocytes in the skeleton, glial cells in the nervous system, Sertoli cells in the male gonad, cells in the endocardial cushions in the heart and others. We have previously shown that Sox9 also inhibits proliferation of chondrocytes and have proposed that this occurs through the inhibition of the transcriptional activity of β-catenin by Sox9. To clarify the function of Sox9 in the intestine, we inactivated the Sox9 gene in the intestine using the Cre recombinase /LoxP recombination system. In Villin-Cre transgenic mice, Cre is expressed in all intestinal epithelial cells, which enables the deletion of Sox9 gene throughout the small intestine. Immunohistochemical staining using Sox9 antibodies showed almost complete absence of Sox9 expression in the intestinal epithelium of Sox9floxed/floxed;VillinCre mice. Histological analysis of mutant miceshowed an overall normal morphology of crypts and villi, but the cells in the bottom of the crypts did not show the typical granules of Paneth cells. In the knock-out mice those cells were negative for Lysozyme, an early marker for Paneth cells. Whereas in wild type mice Paneth cells were negative for the proliferation marker Ki67, in Sox9 mutants cells in the bottom of the crypts were positive for Ki67. Thus in the mutant there is a marked expansion of the domain of proliferationg cells in the crypts. We also noted that the length from pylorus to cecum of the Sox9floxed/floxed;VillinCre mice is longer than that of littermate controls. Our results indicate that Sox9 is required for the differentiation of Paneth cells from progenitor cells and suggest the hypothesis that Sox9 may participate in the control of intestinal epithelial cell proliferation.
A Biodegradable Stent with Surface Functionalization of Combined‐Therapy Drugs for Colorectal Cancer
Authors: Xusheng Xie, Xiaobin Zheng, Zhifen Han, Yufeng Chen, Zhaozhu Zheng, Bin Zheng, Xiaowen He, Yongfeng Wang, David L. Kaplan, Yi Li, Gang Li, Xiaoqin Wang, Ping Lan
Journal: Advanced Healthcare Materials (2018)

Abstract In‐stent restenosis caused by tumor ingrowth is a major problem for patients undergoing stent placement because conventional stents often lack sustainable antitumor capabilities. The aim of this work is to develop a silk fibroin (SF)‐based nanofibrous membrane that is loaded with combined‐therapy drugs by using electrospinning technologies, which is further coated on a polydioxanone (PDO) stent and used for the treatment of colorectal cancer (CRC). In order to improve treatment effectiveness, a combination of therapeutic drugs, i.e., curcumin (CUR) and 5‐fluorouracil (5‐FU), is dissolved into SF solution and then eletrospun onto the surface of the PDO stent. The morphology, secondary structure, and in vitro drug release profiles of the membranes are characterized. The antitumor efficacy is assessed in vitro and in vivo using a human CRC cell line and normal cells, and tumor‐bearing nude mice. In vitro and in vivo studies on the nanofibrous memembrane‐coating demonstrate improved antitumor effects for the CUR/5‐FU dual drug system which can be attributed to cell cycle arrest in the S phase in association with induced apoptosis in tumor cells by blocking signal transducer and activator of transcription3 (Stat3) and nuclear factor kappa beta (NF‐kB) signaling pathways, suggesting potential in the treatment of CRC in the future.
Abstract 14179: Risk Factors for the Left Atrial Appendage Thrombus in Patients Taking Appropriate Oral Anticoagulation With Atrial Fibrillation
Authors: Satoshi Takahashi, Takanao Mine, Kenki Ashida, Hideyuki Kishima, Masaharu Ishihara, Tohru Masuyama
Journal: Circulation (2016)

Background: Cardiogenic cerebral infarction has been reported despite taking appropriate oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation (AF). They might need additional therapy such as percutaneous left atrial appendage closure. We examined the risk factors for left atrial appendage thrombus (LAAT) in patients during taking appropriate OAC with non-valvular AF. Method: We retrospectively studied 703 consecutive patients (age 67±11, 488 men, 306 with paroxysmal AF) who take oral anticoagulation (OAC) therapy (392 with warfarin and 311 with direct oral anticoagulants; DOACs) more than one month who underwent transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) prior to cardioversion or catheter ablation for AF. Clinical data, CHADS2, CHADS2-VASc and TTE parameters were evaluated. Results: LAAT were detected in 57/703 patients (8%) using TEE. Patients with LAAT showed a high rate of warfarin taking [43/392 (11 %) with warfarin v.s. 14 /311 (5%) with DO...
Hereditary cancer syndromes and development of tele genetics program in the Asia-Pacific, Middle East region
Authors: R. Khoury, S. Dawood, M. Khoury, F. Khan, F. Al Khatib, M. Bello, A. Hamadi, H. Kazim, A. Dhar, G. Nasioulas
Journal: Annals of Oncology (2018)
Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men
Authors: Andreas Walther, Jonas Breidenstein, Robert Miller
Journal: JAMA Psychiatry (2018)

Countering depressive disorders is a public health priority. Currently, antidepressants are the first-line treatment, although they show modest effects. In men, testosterone treatment is a controversial alternative or adjunct treatment option.To examine the association of testosterone treatment with alleviation of depressive symptoms in men and to clarify moderating effects of testosterone status, depression status, age, treatment duration, and dosage.English-language studies published in peer-reviewed journals identified from PubMed/Medline, Embase, Scopus, PsychINFO, and the Cochrane Controlled Trials Register from database inception to March 5, 2018, using the search terms testosterone, mood, administration, dosage, adverse effects, deficiency, standards, therapeutic use, therapy, treatment, and supplementation.Randomized placebo-controlled clinical trials (RCTs) of testosterone treatment that together cover a broad age range and hypogonadal or eugonadal men reporting depressive symptoms on psychometrically validated depression scales.Of 7690 identified records, 469 were evaluated against full study inclusion criteria after removing duplicates, reviews, and studies that did not examine male patients or testosterone. Quality assessment and data extraction from the remaining 27 RCTs were performed.Primary outcomes were testosterone treatment effectiveness (standardized score difference after treatment), efficacy (proportion of patients who responded to testosterone treatment with a score reduction of 50% or greater), and acceptability (proportion of patients who withdrew for any reason).Random-effects meta-analysis of 27 RCTs including 1890 men suggested that testosterone treatment is associated with a significant reduction in depressive symptoms compared with placebo (Hedges g, 0.21; 95% CI, 0.10-0.32), showing an efficacy of odds ratio (OR), 2.30 (95% CI, 1.30-4.06). There was no significant difference between acceptability of testosterone treatment and placebo (OR, 0.79; 95% CI, 0.61-1.01). Meta-regression models suggested significant interactions for testosterone treatment with dosage and symptom variability at baseline. In the most conservative bias scenario, testosterone treatment remained significant whenever dosages greater than 0.5 g/wk were administered and symptom variability was kept low.Testosterone treatment appears to be effective and efficacious in reducing depressive symptoms in men, particularly when higher-dosage regimens were applied in carefully selected samples. However, given the heterogeneity of the included RCTs, more preregistered trials are needed that explicitly examine depression as the primary end point and consider relevant moderators.
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers
Authors: Daniel Heim, Grégoire Montavon, Peter Hufnagl, Klaus-Robert Müller, Frederick Klauschen
Journal: Genome Medicine (2018)

Comprehensive mutational profiling data now available on all major cancers have led to proposals of novel molecular tumor classifications that modify or replace the established organ- and tissue-based tumor typing. The rationale behind such molecular reclassifications is that genetic alterations underlying cancer pathology predict response to therapy and may therefore offer a more precise view on cancer than histology. The use of individual actionable mutations to select cancers for treatment across histotypes is already being tested in the so-called basket trials with variable success rates. Here, we present a computational approach that facilitates the systematic analysis of the histological context dependency of mutational effects by integrating genomic and proteomic tumor profiles across cancers. To determine effects of oncogenic mutations on protein profiles, we used the energy distance, which compares the Euclidean distances of protein profiles in tumors with an oncogenic mutation (inner distance) to that in tumors without the mutation (outer distance) and performed Monte Carlo simulations for the significance analysis. Finally, the proteins were ranked by their contribution to profile differences to identify proteins characteristic of oncogenic mutation effects across cancers. We apply our approach to four current proposals of molecular tumor classifications and major therapeutically relevant actionable genes. All 12 actionable genes evaluated show effects on the protein level in the corresponding tumor type and showed additional mutation-related protein profiles in 21 tumor types. Moreover, our analysis identifies consistent cross-cancer effects for 4 genes (FGFR1, ERRB2, IDH1, KRAS/NRAS) in 14 tumor types. We further use cell line drug response data to validate our findings. This computational approach can be used to identify mutational signatures that have protein-level effects and can therefore contribute to preclinical in silico tests of the efficacy of molecular classifications as well as the druggability of individual mutations. It thus supports the identification of novel targeted therapies effective across cancers and guides efficient basket trial designs.
Nitric oxide decreases the transcription repressor activity of Yin-Yang 1 (YY1) via S-nitrosylation: Role in the immunosensitization of tumor cells to apoptosis
Authors: Fumiya Hongo, Hermes Garban, Sara Huerta-Yepez, Mario Vega, Ali Jazirehi, Yoichi Mizutani, Benjamin Bonavida
Journal: Cancer Research (2004)

4356  Yin-Yang 1 (YY1) is a transcription factor that may activate or repress gene expression. We have reported the upregulation of the TNF receptor family members by nitric oxide (NO) resulting in the sensitization of tumor cells (e.g. ovarian, prostate, lymphoma) to TNF family-mediated apoptosis. The sensitization by NO was suggested to be mediated in part to S-nitrosylation of the transcription repressor YY1 and consequently, the inhibition of its DNA-binding activity in the silencer region of the receptor promoter. In this study, we examined the direct S-nitrosylation of YY1 using the human prostate cancer cell line, PC-3, as model. Culture cells were incubated for 18 h in the presence of various concentrations of the NO donor DETANONOate (500 μM, 1000 μM) that sensitized PC-3 to Fas ligand- and TRAIL-mediated apoptosis. Subsequently, we analyzed for S-nitrosylation of YY1 by various methods. Using immunohistochemistry, we found that general S-nitrosylation of proteins was increased after treatment with NO. Noteworthy, significant constitutive S-nitrosylated proteins were detected. Further, using double immunofluorescence staining microscopy, we colocalized the presence of S-nitrosylated proteins and YY1. In addition, a specific significant increase in YY1-SNO protein was determined in culture cells exposed to NO by immunoprecipitation with anti-Cys SNO antibody followed by immunodetection of YY1. These findings were corroborated by demonstrating that immunoprecipitation of NO-treated PC-3 cells by anti-SNO antibody revealed that YY1 was S-nitrosylated using the method by Miles et al (Meth Enzym., 268:105, 1996). These findings altogether reveal a novel mechanism of YY1 regulation by nitric oxide showing direct S-nitrosylation of this transcription repressor, the consequent decrease in DNA-binding activity and derepression of gene transcription. This work was supported by a grant from the Department of Defense (DAMD 17-02-1-0023), the UCLA SPORE in Prostate Cancer (P50 CA92131-01A1), the Jonsson Comprehensive Cancer Center (AJ), UC-MEXUS (SH-Y), and a grant from Fogarty (SH-Y, HG, MV).
Induction chemotherapy with docetaxel plus cisplatin followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: 8-year follow-up
Authors: A.M.A. Al-Humiqani, A.M. Maklad, A. Alyamany, K. Taher, R.M. Akasha, M. Alsenosy, M. Omran, H. Alhussain, H. Bakhribah, A. Alzahrani, A. Marie, S.F. Aldahri, K.H. Al-Qahtani, R.A. Mohamed, Y. Bayoumi
Journal: Annals of Oncology (2018)
“From the Lab to the Pitch”: the 6th ECOSEP congress with INSEP
Authors: Nikolaos Malliaropoulos, Jean-François Kaux, Alain Frey, Heinz Lohrer
Journal: British Journal of Sports Medicine (2018)

This European College of Sports and Exercise Physicians (ECOSEP) edited issue of BJSM highlights the multidisciplinary nature of sport and exercise medicine. You’ll find valuable information relating to topics such as internal workload during training, musculoskeletal sports medicine, endocrinology, on-the-field medical services. Sports medicine spans from the microlevel (molecular and cellular responses) of medicine to the mesolevel (mechanical properties, clinical practice) as well as the macrolevel (population-based epidemiology).

Prediction of injury risk is hotly debated1 and Scotland’s Dr Alan McCall et al . ( see page 1517 ) discusses the ability of variables/risk factors to predict sports injuries. Internal workload (self-rated perceived exertion) both in training and matches appears to be a useful measure for team practitioners to consider.

Emergency Action Protocols are essential to ensure athlete safety during training and competition. In a very practical educational review ( see page 1535 ), UK’s Dr Rohi Shah introduces the concept of the ’BOARD'. …
Metabolic Alterations May Contribute to Cabozantinib Resistance in Acute Myeloid Leukemia Cells with FLT3-ITD
Authors: Fang-Yu Lo, Kit Man Ng, Wen-Chun Chen, Chung-Yi Hu, Hsin-An Hou, Cheng-Hong Tsai, Da-Liang Ou, Hwei-Fang Tien, Liang-In Lin
Journal: Blood (2018)
Abstract 17490: Risk Stratification of Maternal, Fetal and Neonatal Outcome in Rheumatic Heart Disease
Authors: Yuwei Fu, Yanping Ruan, Lin Sun, Shuping Ge, Yihua He
Journal: Circulation (2017)

Background and Objectives: There is little data in maternal and fetal outcome in patients with rheumatic heart disease (RHD). We sought to examine the “natural history” of RHD patients and risk fac...
Clinical benefits of later line trabectedin and eribulin treatment for soft tissue sarcoma (STS) after pazopanib treatment from the Nishinomiya Sarcoma Cohort Study (NSCS)
Authors: H. Narahara, M. Morimoto, E. Tanaka, S. Ueda, Y. Yasunaga, Y. Inui, K. Takahashi, S. Kawata
Journal: Annals of Oncology (2018)
Pollution: London’s low emission zone has improved air quality but not children’s lungs, study finds
Authors: Susan Mayor
Journal: BMJ (2018)

Introducing a low emission zone in London has improved air quality by modestly reducing nitrogen oxides in highly polluted areas but is not associated with improvements in children’s respiratory health or lung function, an observational study has found.1

Results published in the Lancet Public Health showed that continued exposure to nitrogen dioxide (NO2) equated to an average decrease in children’s lung capacity of around 5% in the five years after the zone was implemented, and this was inversely correlated with higher exposure to air pollutants.

“Although changes of this magnitude are unlikely to cause problems in healthy children, we urgently need to know whether these lung deficits will impact lung function and health in later life,” said …
On the Link Between Concussions and Suicide
Authors: Donald A. Redelmeier, Junaid A. Bhatti
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 19973: Takotsubo Syndrome Associated miR-16 and miR-26a Reduce Contractility of Apical, but Not Basal, Cardiomyocytes in vitro
Authors: Liam Couch, Rory Clayton, Laura Wienecke, Anselm A Derda, Cesare Terracciano, Thomas Thum, Sian E Harding
Journal: Circulation (2017)

Introduction: Takotsubo syndrome (TTS) is a severe but reversible acute heart failure affecting predominantly post-menopausal women. Extreme adrenaline levels arising with stress cause ventricular ...
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
Authors: Roberta D'Ambrosio, Luisa Pasulo, Massimo Puoti, Maria Vinci, Monica Schiavini, Sergio Lazzaroni, Alessandro Soria, Federico Gatti, Barbara Menzaghi, Alessio Aghemo, Francesca Capelli, Maria Grazia Rumi, Lorenzo Morini, Alessia Giorgini, Marie Graciella Pigozzi, Angelo Rossini, Franco Maggiolo, Angelo Pan, Massimo Memoli, Ombretta Spinelli, Paolo Del Poggio, Valeria Saladino, Angiola Spinetti, Anna De Bona, Andrea Capretti, Caterina Uberti-Foppa, Paolo Bonfanti, Natalia Terreni, Fernanda Menozzi, Alberto Eraldo Colombo, Omar Giglio, Riccardo Centenaro, Marta Borghi, Chiara Baiguera, Viviana Picciotto, Simona Landonio, Andrea Gori, Carlo Magnani, Franco Noventa, Stefania Paolucci, Pietro Lampertico, Stefano Fagiuoli
Journal: Journal of Hepatology (2018)
Animal protein intake and hepatic steatosis in the elderly: authors' response
Authors: Louise Johanna Maria Alferink, Jessica Christina Kiefte-de Jong, Sarwa Darwish Murad
Journal: Gut (2018)

We would like to thank Tang and Mann for their interest in our study in which we showed that animal protein intake was independently associated with higher prevalence of non-alcoholic fatty liver disease (NAFLD) in an overweight, predominantly aged Caucasian population.1 2 

Rightfully so, the authors express their concerns regarding the generalisability of our findings towards younger patients with clinically significant non-alcoholic steatohepatitis (NASH).1 Indeed, our results only pertain to our study population, consisting of an elderly and presumably healthy population in which the vast majority will have NAFLD, not NASH. Nonetheless, we …
Evaluation of Symptom and Side Effect Bother in Cutaneous T-Cell Lymphoma Patients Treated with Mogamulizumab or Vorinostat
Authors: Stacie Hudgens, Pierluigi Porcu, Pietro Quaglino, Auris Huen, Lysbeth Floden, Mollie Leoni, Madeleine Duvic
Journal: Blood (2018)